SEIC 39.48 Sei Investments Company $SEIC Hit a 52 week high

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
SEIC 39.48 Sei Investments Company $SEIC Hit a 52 week high of 39.50 Closing the day 11/10/14 at 39.48 +0.24 +0.61% With a day low of 39.15 and a total volume of 445,716.

SEIC Recent Posts: http://investorshangout.com/SEI-Investments-C...EIC-55396/

SEIC Sei Investments Company Recent Headline News

SEI Investments Earnings Hindsight: Up 7.3% in Last 19 Days (SEIC)
Comtex SmarTrend(R) - Mon Nov 10, 11:47AM CST
When SEI Investments (NASDAQ:SEIC) reported earnings 19 days ago on October 22nd, 2014, analysts, on average, expected the company to report earnings of $0.47 on sales of $319.4 million. SEI Investments actually reported earnings of $0.49 per share on sales of $322.0 million, beating EPS estimates by $0.02 and beating revenue estimates by $2.6 million. Since the company's report, shares of SEI Investments have risen from $36.57 to $39.24, representing a gain of 7.3% in the past 19 days.
SEIC: 39.48 (+0.24)

Insider Trading Alert - CRZO, SEIC And MOH Traded By Insiders
at The Street - Mon Nov 10, 10:00AM CST
Stocks with insider trader activity include CRZO, SEIC and MOH
SEIC: 39.48 (+0.24), CRZO: 50.72 (-2.66), MOH: 49.55 (+0.80)

Why is Fortress Investment Up Despite Q3 Earnings Miss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 12:00PM CST
Higher expenses dragged results of Fortress Investment Group LLC (FIG) and it consequently failed to deliver a positive earnings surprise
SEIC: 39.48 (+0.24), FIG: 7.33 (+0.01), BLK: 350.70 (-0.78), AMP: 130.16 (+1.11)

Apollo Global (APO) Q3 Earnings Miss on Lower Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 9:50AM CST
Dismal performance in the private equity segment dragged third-quarter 2014 results of Apollo Global Management, LLC (APO)
SEIC: 39.48 (+0.24), APO: 23.45 (+0.07), BLK: 350.70 (-0.78), AMP: 130.16 (+1.11)

MacKay Shields Expands Defined Contribution Capabilities with Introduction of Two Collective Investment Trusts
Business Wire - Tue Oct 28, 8:15AM CDT
--Firm Introduces Unconstrained Bond and Core Plus Bond Collective Investment Trusts
SEIC: 39.48 (+0.24)

SEI Investments Gains on Q3 Earnings Beat, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 9:30AM CDT
Shares of SEI Investments (SEIC) rose 2.1% following its third-quarter 2014 earnings release before the opening bell. Earnings of 49 cents per share came ahead of the Zacks Consensus Estimate of 46 cents.
SEIC: 39.48 (+0.24), IVZ: 41.17 (-0.11), AMP: 130.16 (+1.11), WDR: 48.35 (-0.17)

SEI Investments' (SEIC) CEO Al West on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 7:33PM CDT

SEIC: 39.48 (+0.24)

Watch for SEI Investments to Potentially Pullback After Gaining 2.09% Yesterday
Comtex SmarTrend(R) - Wed Oct 22, 5:27PM CDT
SEI Investments (NASDAQ:SEIC) traded in a range yesterday that spanned from a low of $35.75 to a high of $36.88. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $35.86 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SEIC: 39.48 (+0.24)

SEI Investments (SEIC) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Oct 22, 12:55PM CDT

SEIC: 39.48 (+0.24)

More on SEI Investments Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 9:39AM CDT

SEIC: 39.48 (+0.24)

Asset Management and Custody Banks Stocks Technical Data - Janus Capital, Franklin Resources, Invesco, WisdomTree Investments, and SEI Investments
PR Newswire - Wed Oct 22, 7:50AM CDT
Investor-Edge has initiated coverage on the following equities: Janus Capital Group Inc. (NYSE: JNS), Franklin Resources Inc. (NYSE: BEN), Invesco Ltd (NYSE: IVZ), WisdomTree Investments Inc. (NASDAQ: WETF), and SEI Investments Company (NASDAQ: SEIC). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 21, 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow Jones Industrial Average advanced 1.31%, to finish the day at 16,614.81, and the S&P 500 closed at 1,941.28, up 1.96%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Financials Sector Index ended the day at 308.10, up 1.87%, with the index also advancing 3.82% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
SEIC: 39.48 (+0.24), IVZ: 41.17 (-0.11), JNS: 15.18 (-0.13), WETF: 15.64 (+0.04), BEN: 56.57 (-0.41)

SEI Investments beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 7:43AM CDT

SEIC: 39.48 (+0.24)

SEI beats 3Q profit forecasts
Automated Insights - Wed Oct 22, 7:39AM CDT
OAKS, Pa. (AP) _ SEI Investments Co. (SEIC) on Wednesday reported net income of $84 million in its third quarter.
SEIC: 39.48 (+0.24)

SEI Reports Third-Quarter 2014 Financial Results
Marketwired - Wed Oct 22, 7:31AM CDT
SEI Investments Company (NASDAQ: SEIC) today announced financial results for the third-quarter 2014. Diluted earnings per share were $.49 in third-quarter 2014 compared to $.38 in third-quarter 2013. Our tax rate during third-quarter 2014 was 34.7 percent compared to 28.5 percent in third-quarter 2013. This differential in our tax rate equates to a positive impact of $.03 diluted earnings per share to our third-quarter 2013 earnings.
SEIC: 39.48 (+0.24)

Two Financial Technology Stocks To Buy, Analyst Says
at Investor's Business Daily - Mon Oct 20, 1:07PM CDT
Though financial technology stocks underperformed the broader equity markets in the third quarter, Sterne Agee says two stocks in the group are good bets: SEI Investments (SEIC) and Wright Express (WEX). SEI Investments provides technology and asset...
SEIC: 39.48 (+0.24), WEX: 115.40 (+1.57), BLK: 350.70 (-0.78), ADS: 284.99 (+1.38)

Dividend Contenders: 34 Increases Expected By December 31
David Fish - at Seeking Alpha - Sat Oct 18, 5:44PM CDT

CASS: 49.41 (+0.51), MATW: 46.55 (+0.31), SEIC: 39.48 (+0.24), SFG: 68.26 (+0.42), NKE: 94.96 (+1.18), NKSH: 31.92 (+0.44), MDU: 25.95 (-0.41), SJI: 57.98 (-0.48), AEL: 27.84 (+0.64), MSM: 83.81 (+0.16), UMBF: 60.00 (+0.32), AAN: 26.06 (+0.36), YORW: 22.03 (+0.17), SYK: 88.44 (+0.97), ECL: 112.73 (+0.25), AXS: 49.22 (-0.24), WHG: 64.54 (-0.61), JJSF: 103.98 (+0.77), AROW: 27.43 (+0.06), LECO: 74.11 (+0.05), BRO: 32.50 (+0.20), WABC: 50.19 (+0.23), UBA: 22.25 (+0.37), RGLD: 61.95 (-3.47), ANDE: 54.77 (-0.02), UTMD: 58.20 (-0.29), EIX: 63.08 (+0.70), LG: 51.31 (+0.01), PB: 60.68 (+0.56), VGR: 22.10 (+0.25)

SEI to Announce Third-Quarter 2014 Earnings on Wednesday, October 22, 2014
Marketwired - Wed Oct 15, 1:00PM CDT
SEI Investments Company (NASDAQ: SEIC) announced today that it intends to release earnings for the third-quarter 2014 on Wednesday, October 22, 2014, before the market opens. The company will hold a conference call to discuss these financial results beginning at 2 p.m. Eastern time.
SEIC: 39.48 (+0.24)

SEI Investments Remains Focused on Top-Line Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 01, 10:40AM CDT
On Sep 24, 2014, we issued an updated research report on SEI Investments (SEIC).
MRCC: 13.94 (+0.05), SEIC: 39.48 (+0.24), AB: 26.35 (+0.10), JNS: 15.18 (-0.13)

SEI White Paper: Lump Sum Payments Should Be Paired With a De-Risking Portfolio Strategy
Marketwire - Tue Sep 30, 12:30PM CDT
SEI (NASDAQ: SEIC) today released a white paper evaluating the potential impacts of offering lump sum payments to terminated-vested participants of pension plans. Average pension funding levels increased significantly last year, and many plan sponsors are considering the benefits of offloading a portion of plan liabilities through lump sum pay-outs. However, according to SEI's analysis, this strategy works best when used in conjunction with a de-risking portfolio strategy. For plans with a return-seeking strategy in place, which is the majority of U.S. corporate pension plans, lump sum pay-outs could prove counterproductive.
SEIC: 39.48 (+0.24)

SEI Investments Downgraded to Hold on Expense Concerns - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 10:40AM CDT
On Sep 30, Zacks Investment Research downgraded SEI Investments (SEIC) to a Zacks Rank #3 (Hold).
SEIC: 39.48 (+0.24), AB: 26.35 (+0.10), BX: 31.70 (+0.56), JNS: 15.18 (-0.13)

SEI Investments Company (SEIC) Stock Research Links

SEIC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 9

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 4

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 3

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 5

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 6

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 3

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 4

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading

Top 5 Most Recently Viewed Articles

Soleno Therapeutics Celebrates FDA Approval of VYKAT XR for PWS

Updated Category News Views 420

Soleno Therapeutics Announces FDA Approval for VYKAT XR Soleno Therapeutics, Inc. (NASDAQ: SLNO), a notable biopharmaceutical company, has made a significant announcement regarding the U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets. This new treatment targets hyperphagia in individuals aged four and older...

Continue Reading
aTyr Pharma Faces Legal Challenges: Investors Urged to Act

Updated Category News Views 173

aTyr Pharma's Legal Situation and Its Implications Recent developments surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) have caught the attention of investors, particularly as the company faces significant legal challenges. The situation arose from a steep decline in share value triggered by disappointing results from a key clinical trial. This decline, marked by an...

Continue Reading
Primo Brands Boosts Share Repurchase Program by $50 Million

Updated Category News Views 145

Primo Brands Boosts Share Repurchase Program Primo Brands Corporation (NYSE: PRMB) is excited to announce a significant increase in its share repurchase program. This decision, made by the Board of Directors, involves raising the repurchase authorization by $50 million, bringing the total program authorization to an impressive $300 million. This enhancement in the share...

Continue Reading
GOTRAX Partners with RSMG Select to Inspire Youth Movement

Updated Category News Views 83

GOTRAX Teams Up with RSMG Select for Youth Development GOTRAX has embarked on an inspiring journey through its partnership with RSMG Select, aimed at nurturing not just young athletes but the community at large. The collaboration has transformed the experience for youth participating in futsal, allowing for significant growth and empowerment beyond the typical sports...

Continue Reading
Zenas BioPharma Celebrates Major Milestones in Q3 2025

Updated Category News Views 245

Zenas BioPharma Celebrates Major Milestones in Q3 2025 - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end. - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS). - Secured development and commercialization rights for three...

Continue Reading